A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients

Movement Disorders

Volumn 13, Issue 4, 1998, Pages 643-647

  Hauser, Robert A ^a   Molho, Eric ^b   Shale, Heidi ^c   Pedder, Simon ^d   Dorflinger, Ernest E ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c East Bay Neurology   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

COMT inhibitors; Early therapy; Parkinson's disease; Selegiline; Tolcapone

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE; DOPAMINE; LEVODOPA; SELEGILINE; TOLCAPONE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINE; VERTIGO;

EID: 7344259588     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130406     Document Type: Article

References (10)

1. Napolitano A, Zurcher G, Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol 1995;273:215-221.
2. Tuomainen P, Tornwall M, Mannisto PT. Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anesthetized rats. Pharmacol Toxicol 1996;78:392-396.
3. Kaakola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 1994;25:813-824.
4. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 1997;49:665-671.
5. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:881-887.
6. Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-dopa pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 1995;18:333-337.
7. Dingemanse J, Jorga K, Zurcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-262.
8. Tohgi H, Abe T, Yamazaki K, Saheki M, Takahashi S, Tsukamoto Y. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 1995;192:165-168.
9. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
10. Kaakkola S, Wurtman RJ. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res 1992;587:241-249.